PCN137 COST COMPARISON OF ADVERSE EVENTS AND TREATMENT ADMINISTRATION OF LURBINECTEDIN VERSUS INTRAVENOUS TOPOTECAN FOR RELAPSED SMALL CELL LUNG CANCER IN SPAIN AND THE UNITED KINGDOM

Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.333
https://www.valueinhealthjournal.com/article/S1098-3015(19)32711-1/fulltext
Title : PCN137 COST COMPARISON OF ADVERSE EVENTS AND TREATMENT ADMINISTRATION OF LURBINECTEDIN VERSUS INTRAVENOUS TOPOTECAN FOR RELAPSED SMALL CELL LUNG CANCER IN SPAIN AND THE UNITED KINGDOM
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32711-1&doi=10.1016/j.jval.2019.09.333
First page :
Section Title :
Open access? : No
Section Order : 10271
Categories :
Tags :
Regions :
ViH Article Tags :